The receptor mechanism is established, and blocking the receptor removes the effect
1 / 6
PDRN is a mixture of short DNA fragments, conventionally purified from salmon sperm or testes and usually described as 50 to 1,500 kilodaltons in size. It works through two routes at once. It binds the adenosine A2A receptor, the receptor that endogenous adenosine uses to resolve inflammation, and it supplies nucleotides to the salvage pathway cells use to rebuild DNA.
A molecule of that size does not cross skin on its own
2 / 6
Two physical facts drive the formulation work across every area here. PDRN is large and heavily negatively charged, so intact skin is a poor route. And it is DNA, so nucleases in the skin and in a water-based emulsion dismantle it before it acts.
Market
The home premium is already being competed away
3 / 6
Domestic medical-device growth fell from 93.5 percent to 6.2 percent. The company attributes it to a 2025 medical-tourism base, but competitor Lituo is growing faster and extracellular-matrix products are projected to move from 3.9 to 17.3 percent penetration against Rejuran.
Strategy
China is solving manufacturing, Korea is solving the label
4 / 6
One hundred and sixty-nine Chinese patent publications in 2026 against 83 Korean, from 14 and 11 in 2021. Chinese offices account for 90 of the 197 sourcing documents.
Research
A carrier buys a measured gain of about twenty percent
5 / 6
The published measurement is short enough to quote in full. A PDRN nanoliposome came out at 125 nanometres with 81.3 percent encapsulation, and over 24 hours its cumulative skin permeation was 1.22 times that of free PDRN with 1.40 times the skin retention.
Market
China registered tens of thousands of cosmetics and has approved no injectable
6 / 6
Registration is the cheap step: more than 17,000 cosmetic products containing sodium DNA, the ingredient name PDRN is registered under, were registered in China in the first half of 2025. Around 4,000 brands are in the category, and combined sales on Tmall, JD.com and Douyin rose from 1.5 million yuan in 2022 to 408 million in 2025, with 223 million in the first four months of 2026. Rejuran Cosmetics entered Sephora China in December 2025.
Research
What is being built
Documents by area
197
147
125
53
22
13
Market
What reaches buyers
Market news · Not available. News wasn't included when this radar was set up.
The commercial record belongs to one country and one company
Korea's polynucleotide injectables market was USD 88.0 million in 2025 and is projected to reach USD 321.8 million by 2033, about 16.8 percent a year, with Korea holding 35.9 percent of the global total. PharmaResearch reported first-quarter 2026 revenue of 146.1 billion won, up 25 percent, with operating profit up 28 percent to 57.3 billion won and exports at 40 percent of revenue. Second-quarter revenue reached 178.7 billion won with cosmetics exports up 124 percent, and the company runs near a 40 percent operating margin.
Strategy
Where the money goes
Market news · Not available. News wasn't included when this radar was set up.
The centre of gravity has moved upstream
Across the six areas covered here, patent publications are distributed very differently from the commercial market. Sourcing and extraction, the work of getting intact DNA out of a tissue and cutting it to a length, holds 197 publications. Delivery and formulation holds 147, topical formulations 125. The injectable area, where the revenue, the clinical evidence and the regulatory scrutiny all sit, holds 53.